

Article

Enantioselective Benzylation and Allylation of α -Trifluoromethoxy Indanones under Phase-Transfer Catalysis

Yumeng Liang¹, Mayaka Maeno¹, Zhengyu Zhao¹, and Norio Shibata^{1,2,*}

¹ Department of Nanopharmaceutical Sciences, Department of Life Science and Applied Chemistry, Nagoya Institute of Technology Gokiso, Showa-ku, Nagoya 466-8555, Japan; y.liang.763@stn.nitech.ac.jp (Y.L.); tamag0_nek0@yahoo.co.jp (M.M.); z.zhao.317@stn.nitech.ac.jp (Z.Z.)

² Institute of Advanced Fluorine-Containing Materials, Zhejiang Normal University, 688 Yingbin Avenue, 321004 Jinhua, China.

* Correspondence: nozshiba@nitech.ac.jp; Tel. /Fax: +81-52-735-7543

Abstract: The organo-catalyzed enantioselective benzylation reaction of α -trifluoromethoxy indanones afforded α -benzyl- α -trifluoromethoxy indanones with a tetrasubstituted stereogenic carbon center in excellent yield with moderate enantioselectivity (up to 57% ee). Cinchona alkaloid-based chiral phase transfer catalysts were found to be effective for this transformation, and both enantiomers of α -benzyl- α -trifluoromethoxy indanones were accessed, depended on the use of cinchonidine and cinchonine-derived catalyst. The method was extended to the enantioselective allylation reaction of α -trifluoromethoxy indanones to give the allylation products in moderate yield with good enantioselectivity (up to 76% ee).


Keywords: trifluoromethoxy; fluorine; enantioselective; phase-transfer catalyst; organo-catalysis

1. Introduction

The role of fluorine in medicinal chemistry is expanding rapidly after it was discovered that the introduction of fluorine into an organic molecule can productively influence its physical and chemical properties.[1-14] In particular, the trifluoromethoxy (OCF₃) functional group has received extensive attention in recent years in the fields of pharmaceuticals and agrochemicals, owing to its unique three-dimensional electronic properties, suitable lipophilic properties, and good metabolic stability.[15-20] In fact, the OCF₃ group is present in more than 1393 biologically active organic compounds according to a check of the PubChem database in June 2019.[21-23] Compared to trifluoromethyl (CF₃) ($\pi\chi = 0.88$), methyl (CH₃) ($\pi\chi = 0.52$) and methoxy (OCH₃) groups ($\pi\chi = -0.02$), the OCF₃ group has the highest lipophilicity value ($\pi\chi = 1.04$) [24-30] resulting in the potential improvement of metabolic profiles, including permeability and absorption, when it is introduced into the appropriate position of parent molecules.

In contrast to the requirement of OCF₃-containing drug candidates in medicinal chemistry, the synthesis of OCF₃-containing organic compounds is relatively problematic. The OCF₃ unit is traditionally synthesized from its chlorinated precursor, the trichloromethoxy (OCCl₃) moiety, by a chlorine/fluorine exchange reaction under harsh reaction conditions.[31-36] The OCF₃ anion is unstable and decomposes rapidly into difluorophosgene (O=CF₂) and a fluoride anion (F⁻) which can make nucleophilic trifluoromethylation difficult.[37] The electrophilic trifluoromethylation of hydroxyl compounds is another strategy, but the method is somewhat limited. While the synthesis of OCF₃-containing organic compounds has improved dramatically over the last five years [38-43], a method that can be used to construct a chiral "C*-OCF₃" unit is still extremely scarce. In 2017, Tang and co-workers reported the enantioselective bromo-trifluoromethoxylation of olefins by trifluoromethyl arylsulfonate (TFMS) under silver catalysis (Scheme 1a).[44] Later, Shen and co-workers reported a method to construct chiral trifluoromethoxyl compounds by the Ni-catalyzed enantioselective Suzuki–Miyaura coupling of secondary benzyl bromides in good to high

enantioselectivity (Scheme 1b).[45] We developed a strategy for the synthesis of chiral, non-racemic α -OCF₃-ketones with a tetrasubstituted carbon center via a Pd-catalyzed enantioselective Tsuji-allylation reaction with high enantioselectivity (Scheme 1c).[46, 47] Very recently, Liu and co-workers reported the Pd-catalyzed enantioselective intramolecular trifluoromethoxylation reaction of alkenes using CsOCF₃ to furnish OCF₃-compounds with a chiral stereogenic center (Scheme 1d).[48] While these methods have broad substrate scopes with high enantioselectivity, all the methods require transition metal catalysts. Herein, we report the first example of constructing molecules with an OCF₃ chiral center under non-metallic, organocatalytic conditions. The α -OCF₃ indanones react with benzyl bromides in the presence of a cinchona alkaloid-derived chiral phase-transfer catalyst (PTC) to afford enantioenriched α -benzyl- α -OCF₃ indanones in high yield with up to 57% ee. Access to both (*R*)- and (*S*)-enantiomers of α -benzyl- α -OCF₃ indanones can be controlled by the catalysts. The method was expanded to the enantioselective allylation reaction with allyl bromide to provide α -allyl- α -OCF₃ indanones with up to 76% ee (Scheme 1e).




Scheme 1. Enantioselective synthesis of trifluoromethoxy-containing compounds.

2. Results and Discussion

The enantioselective benzylation of α -OCF₃-substituted indanone **1a** with benzyl bromide (**2a**) was first examined (Table 1). The screening of representative cinchonine-derived PTCs, CN-1–CN-8 (entries 1–8) in toluene revealed that *N*-[4-(trifluoromethyl)benzyl]cinchoninium bromide CN-4 exhibited potential performance with 88% yield with 26% ee of (+)-**3aa**. We next examined solvents (*n*-hexane, dichloromethane (DCM), tetrahydrofuran (THF), and diethyl ether (Et₂O)), but no satisfying consequences were observed (entries 9–12). Bases were next examined (potassium carbonate (K₂CO₃), sodium hydroxide (NaOH), cesium hydroxide monohydrate (CsOH·H₂O),

lithium hydroxide (LiOH), sodium hydride (NaH), potassium acetate (KOAc) and dipotassium phosphate (K_2HPO_4) (entries 13–19). Among these, CsOH·H₂O exhibited the best performance (83% yield) with 43% ee of (+)-**3aa**. Additional solvent screening using CsOH·H₂O (benzotrifluoride (PhCF₃), toluene: CHCl₃ = 7:3) (entries 20–21) revealed no improvement in the results. The concentration of the reaction (0.1 M to 0.02 M) and the temperature affected selectivity (entries 22–25), and the best results obtained were 80% yield with 54% ee (entry 25). The product with an opposite configuration, (–)-**3aa** was obtained in 75% yield with 50% ee using **CD-4** (entry 26). More optimization results using other PTC were shown in the supporting information (SI) (Table S1, in SI).

Table 1. Optimal condition screening ¹




Entry	Cat.	Base	Solvent	Time	Yield (%) ⁶	ee (%) ⁷
1	CN-1	KOH	toluene	15	73	1
2	CN-2	KOH	toluene	15	75	3
3	CN-3	KOH	toluene	15	82	14
4	CN-4	KOH	toluene	15	88	26
5	CN-5	KOH	toluene	15	82	14
6	CN-6	KOH	toluene	15	89	0
7	CN-7	KOH	toluene	15	67	0
8	CN-8	KOH	toluene	15	78	0
9	CN-4	KOH	<i>n</i> -hexane	24	38	2
10	CN-4	KOH	DCM	24	65	5
11	CN-4	KOH	THF	24	68	5
12	CN-4	KOH	Et ₂ O	24	40	19
13	CN-4	K ₂ CO ₃	toluene	48	11	n.d.
14	CN-4	NaOH	toluene	48	58	4
15	CN-4	CsOH·H ₂ O	toluene	15	83	43
16	CN-4	LiOH	toluene	48	NR	-

17	CN-4	NaH	toluene	48	57	0
18	CN-4	KOAc	toluene	48	NR	-
19	CN-4	K ₂ HPO ₄	toluene	48	NR	-
20	CN-4	CsOH·H ₂ O	PhCF ₃	15	96	9
21	CN-4	CsOH·H ₂ O	toluene:CHCl ₃ = 7:3	24	39	35
22 ²	CN-4	CsOH·H ₂ O	toluene	15	92	49
23 ³	CN-4	CsOH·H ₂ O	toluene	15	83	50
24⁴	CN-4	CsOH·H₂O	toluene	15	80	54
25 ^{4,5}	CN-4	CsOH·H ₂ O	toluene	72	75	57
26 ⁴	CD-4	CsOH·H ₂ O	toluene	15	75	-50


¹ Reaction conditions: **1a** (0.1 mmol, 1.0 equiv), BnBr **2a** (0.15 mmol 1.5 equiv), base (0.2 mmol, 2.0 equiv) and **cat.** (10.0 mol%) were stirred in 1.0 mL of anhydrous toluene at room temperature. ² 2.0 mL of toluene was used. ³ 3.0 mL of toluene was used. ⁴ 5.0 mL of toluene was used. ⁵ Stirred at 0 °C. ⁶ Isolated yields. ⁷ ee was determined by chiral HPLC. CN = cinchonine, CD = cinchonidine.

With the optimal reaction conditions in hand (Table 1, entry 24), we explored the substrate scope of this enantioselective catalytic benzylation of α -OCF₃ indanones **1** (Scheme 2). With a variety of benzyl bromides **2b–2g** under the optimal conditions, the desired OCF₃ indanones (+)-**3ab–3ag** were obtained in good to high yield (63–85%) with moderate ee (24–53%). Indanones with an electron-withdrawing group on the aromatic ring (**1b–1d**) gave the desired products (+)-**3ba–3da** in high to excellent yield (73–93%) with good ee (51–57%). On the other hand, indanones with an electron-donating group (**1e–1g**) furnished products (+)-**3ea** and **3fa** in high to excellent yield, but the ee decreased (13–33% ee). The method was unsuitable for the benzylation of α -OCF₃ tetralone **1h** under the same conditions; the corresponding product **3ha** was detected in 51% yield with 8% ee. The absolute stereochemistry of the (+)-**3** was temporality assigned to be (*R*) based on the results for the enantioselective allylation of **1** with allyl bromide (**2h**) as discussed in the later (see the later part of this paper, Scheme 4).

The substrate scope of the enantioselective benzylation of α -OCF₃ indanones **1** using a catalyst, CN-4, under the same reaction conditions furnished (-)-**3** ((*S*)-**3**) with an opposite configuration in similar yield and up to 50% ee (Scheme 3).




Scheme 2. The enantioselective benzylation of α -trifluoromethoxy ketones **1** under CN-4 catalysis.



Scheme 3. The enantioselective benzylation of α -trifluoromethoxy indanones **1** under **CD-4** catalysis.

It should be noted that the method can be applied for the enantioselective allylation of α -OCF₃ indanones **1** with allyl bromide (**2h**) under **CN-4** or **CD-4** catalysis. The desired (+)- and (-)- α -allyl- α -OCF₃ indanones **3ah** were obtained in moderate yield with up to 70% ee and 76% ee, respectively (Scheme 4). The absolute configurations of **3ah** were determined to be the (*R*)-configuration for (+)-**3ah** and the (*S*)-configuration for (-)-**3ah** by comparing to the optical rotation of reported (*S*)-**3ah** ($[\alpha]^{25}_D = -22.5$).^[46]



Scheme 4. The enantioselective allylation of α -trifluoromethoxy indanones **1** under **CN-4** or **CD-4** catalysis. For (*R*)-**3**, **CN-4** was used. For (*S*)-**3**, **CD-4** was used.

3. Materials and Methods

3.1. General Information

All reagents were used as received from commercial sources, unless specified otherwise. All reactions were performed in oven-dried glassware under a positive pressure of nitrogen. Solvents were transferred via syringe and were introduced into the reaction vessels through a rubber septum. All reactions were monitored by thin-layer chromatography (TLC) carried out on 0.25 mm Merck silica-gel (60-F254). The TLC plates were visualized with UV light (254 nm) and *p*-Anisaldehyde in ethanol/heat. Column chromatography was carried out on a column packed with silica-gel 60N spherical neutral size 63-210 μm or 40-63 μm . The ^1H -NMR (300 MHz), ^{19}F -NMR (282 MHz), ^{13}C -NMR (126 MHz) spectra for solution in CDCl_3 were recorded on a Bruker Avance 500, Varian Mercury 300. Chemical shifts (δ) are expressed in ppm downfield from tetramethylsilane ($\delta\text{H} = 0.00$ ppm) or tetramethylsilane ($\delta\text{C} = 0.00$ ppm) or hexafluorobenzene ($\delta\text{F} = -162.20$ ppm). Optical rotations were measured with a Horiba SEPA-300 operating at 589 nm. Mass spectra were recorded on an LCMS-2020EV (ESI-MS) system (Shimadzu Corporation, Kyoto, Japan). High resolution mass spectrometry (HRMS) was recorded on a Waters Synapt G2 HDMS (ESI-MS). Infrared spectra were recorded on a JASCO FT/IR-4100 spectrometer. The wave numbers (ν) of recorded IR-signals are quoted in cm^{-1} on a JASCO FT/IR-4100 spectrometer. HPLC analyses were performed on a JASCO LC-2000 Plus series using 4.6 x 250 mm CHIRALCEL® series or CHIRALPAK series. Melting point were recorded on a BUCHI M-565. All solvents were dried and distilled before use. The ^1H , ^{13}C and ^{19}F NMR spectra of compounds **3** and HPLC data of compounds **3** are available in the Supplementary Material.

3.2. Preparation of α -OCF₃-substituted indanones (General Procedure)

All the substrates, α -OCF₃-indanones **1**, were prepared by following a reported procedure. [46]

General Procedure:

A mixture of the indanone (1.0 equiv) and KOH (3.0 equiv) in MeOH (0.4 M) was stirred for 15 min at 0 °C, and $\text{PhI}(\text{OAc})_2$ (1.1 equiv) was added in 4-5 portions during 5 min. The mixture was stirred at the same temperature for 1 h, then warmed to room temperature and stirred overnight. The mixture was concentrated, dissolved in Et_2O , washed with NaHCO_3 aq., dried over Na_2SO_4 and concentrated, then purified by silica-gel column chromatography. The pure product was then dissolved in EtOH (0.3 M), and 3N HCl aq. (1.0 M) was added. After stirring for 0.5 h at rt, the resulting mixture was extracted with Et_2O , and the combined organic layer was washed with sat. NaHCO_3 aq. and brine, then dried over Na_2SO_4 . The residue can be used without further purification for the next reaction.

A flask was charged with hydroxyketone, AgOTf (3.0 equiv), KF (4.0 equiv) and Selectfluor® (1.5 equiv) in a nitrogen-filled glovebox. Then ethyl acetate (0.2 M), 2-fluoropyridine (3.0 equiv) and Me_3SiCF_3 (3.0 equiv) were added successively under an Ar atmosphere. The resulting mixture was stirred overnight at room temperature. The reaction mixture was filtered through a pad of silica-gel and concentrated. The residue was purified by flash silica-gel column chromatography.

2-(Trifluoromethoxy)-2,3-dihydro-1H-inden-1-one (1a). The reaction was run according to the general procedure, and the product is consistent with previously reported characterization data. [46] ^1H NMR (300 MHz, CDCl_3) δ : 7.82 (d, $J = 6.9$ Hz, 1H), 7.71 – 7.66 (m, 1H), 7.49 – 7.42 (m, 2H), 4.98 – 4.91 (m, 1H), 3.68 (dd, $J = 17.0, 7.9$ Hz, 1H), 3.26 (dd, $J = 17.0, 5.0$ Hz, 1H) ppm. ^{19}F NMR (282 MHz, CDCl_3) δ : -59.66 (s, 3F) ppm.

5-Bromo-2-(trifluoromethoxy)-2,3-dihydro-1H-inden-1-one (1b). The reaction was run according to the general procedure, and the product is consistent with previously reported characterization data. [46] ^1H NMR (300 MHz, CDCl_3) δ : 7.70 – 7.58 (m, 3H), 4.94 – 4.90 (m, 1H), 3.66 (dd, $J = 17.2, 7.9$ Hz, 1H), 3.25 (dd, $J = 17.2, 4.9$ Hz, 1H) ppm. ^{19}F NMR (282 MHz, CDCl_3) δ : -59.82 (s, 3F) ppm.

5-Fluoro-2-(trifluoromethoxy)-2,3-dihydro-1H-inden-1-one (**1c**). The reaction was run according to the general procedure, and the product is consistent with previously reported characterization data. [46] $^1\text{H NMR}$ (300 MHz, CDCl_3) δ : 7.85 (dd, $J = 9.2, 5.4$ Hz, 1H), 7.19 – 7.13 (m, 2H), 4.94 (dd, $J = 7.9, 4.8$ Hz, 1H), 3.67 (dd, $J = 17.3, 7.9$ Hz, 1H), 3.26 (dd, $J = 17.3, 4.9$ Hz, 1H) ppm. $^{19}\text{F NMR}$ (282 MHz, CDCl_3) δ : -59.81 (s, 3F), -99.41 (q, $J = 8.1$ Hz, 1F) ppm.

6-Fluoro-2-(trifluoromethoxy)-2,3-dihydro-1H-inden-1-one (**1d**). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ : 7.48 – 7.37 (m, 3H), 4.96 (dd, $J = 8.0, 4.8$ Hz, 1H), 3.66 (dd, $J = 16.8, 7.9$ Hz, 1H), 3.22 (dd, $J = 16.8, 5.0$ Hz, 1H) ppm. $^{19}\text{F NMR}$ (282 MHz, CDCl_3) δ : -59.85 (s, 3F), -111.30 – -112.37 (m, 1F) ppm. $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ : 196.73 (d, $J = 3.0$ Hz), 162.72 (d, $J = 250.2$ Hz), 145.06 (d, $J = 2.4$ Hz), 135.29 (d, $J = 7.7$ Hz), 128.34 (d, $J = 7.8$ Hz), 124.25 (d, $J = 23.8$ Hz), 121.88 (q, $J = 256.9$ Hz), 110.70 (d, $J = 22.3$ Hz), 76.85 (q, $J = 2.5$ Hz), 33.19 ppm. MS (ESI): m/z 233 (M – H) $^-$.

6-Methyl-2-(trifluoromethoxy)-2,3-dihydro-1H-inden-1-one (**1e**). The reaction was run according to the general procedure, and the product is consistent with previously reported characterization data. [46] $^1\text{H NMR}$ (300 MHz, CDCl_3) δ : 7.62 (s, 1H), 7.50 (d, $J = 7.5$, 1H), 7.35 (d, $J = 7.9$, 1H), 4.92 (dd, $J = 7.9$ Hz, 1H), 3.67 (dd, $J = 17.3, 7.9$ Hz, 1H), 3.26 (dd, $J = 17.3, 4.9$ Hz, 1H) ppm. $^{19}\text{F NMR}$ (282 MHz, CDCl_3) δ : -59.72 (s, 3F) ppm.

6-Methoxy-2-(trifluoromethoxy)-2,3-dihydro-1H-inden-1-one (**1f**). The reaction was run according to the general procedure, and the product is consistent with previously reported characterization data. [46] $^1\text{H NMR}$ (300 MHz, CDCl_3) δ : 7.37 (d, $J = 8.3$, 1H), 7.29 – 7.23 (m, 2H), 4.97 – 4.92 (m, 1H), 3.86 (s, 3H), 3.61 (dd, $J = 16.6, 7.8$ Hz, 1H), 3.18 (dd, $J = 16.6, 4.7$ Hz, 1H) ppm. $^{19}\text{F NMR}$ (282 MHz, CDCl_3) δ : -59.73 (s, 3F) ppm.

5,6-Dimethoxy-2-(trifluoromethoxy)-2,3-dihydro-1H-inden-1-one (**1g**). The reaction was run according to the general procedure, and the product is consistent with previously reported characterization data. [46] $^1\text{H NMR}$ (300 MHz, CDCl_3) δ : 7.24 (d, $J = 14.6$, 1H), 4.90 (dd, $J = 7.6, 4.3$ Hz, 1H), 3.99 (s, 3H), 3.92 (s, 3H), 3.58 (dd, $J = 16.8, 7.6$ Hz, 1H), 3.17 (dd, $J = 16.8, 4.3$ Hz, 1H) ppm. $^{19}\text{F NMR}$ (282 MHz, CDCl_3) δ : -59.61 (s, 3F) ppm.

2-(Trifluoromethoxy)-3,4-dihydronaphthalen-1(2H)-one (**1h**). The reaction was run according to the general procedure, and the product is consistent with previously reported characterization data. [46] $^1\text{H NMR}$ (300 MHz, CDCl_3) δ : 8.07 (d, $J = 7.9$, 1H), 7.54 (t, $J = 7.4$, 1H), 7.37 (t, $J = 7.7$, 1H), 4.85 (dd, $J = 12.1, 4.8$ Hz, 1H), 3.16 (dd, $J = 8.1, 4.4$ Hz, 2H), 2.57 – 2.36 (m, 2H) ppm. $^{19}\text{F NMR}$ (282 MHz, CDCl_3) δ : -59.05 (s, 3F) ppm.

3.3. Representative procedure for the enantioselective catalytic phase transfer benzylation

A flask was charged with α -OCF₃-indanone **1** (0.10 mmol, 1.0 equiv), CsOH·H₂O (0.20 mmol, 2.0 equiv) and **cat. 4** (0.010 mmol, 10.0 mol%) in a nitrogen-filled glovebox. Then anhydrous toluene (5.0 mL, 0.02 M) and **2** (0.15 mmol, 1.5 equiv) was added under an Ar atmosphere. The resulting mixture was stirred overnight or 48 h at room temperature. After that, the solvent was removed under reduced pressure and the residue was purified by flash silica-gel column chromatography.

(+)-2-Benzyl-2-(trifluoromethoxy)-2,3-dihydro-1H-inden-1-one ((+)-**3aa**). The reaction was run according to the general procedure. Eluent (*n*-hexane/ethyl acetate = 15/1). Slightly yellow oil; 24.5mg; 80% yield. The enantiomeric excess (54% ee) was determined by chiral HPLC using CHIRALCEL® OJ-H column (*n*-hexane/isopropanol = 99.0/1.0, flow rate 1.0 mL/min, $\lambda = 254$ nm) t (major) = 16.525 min, t (minor) = 11.367 min. $[\alpha]_D^{25} = +37.7$ (CH_2Cl_2 , $c = 0.62$). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ : 7.78 (d, $J = 7.7$ Hz, 1H), 7.59 (t, $J = 7.4$ Hz, 1H), 7.40 – 7.32 (m, 2H), 7.22 – 7.17 (m, 5H), 3.43 (s, 2H), 3.31 (d, $J = 13.8$ Hz, 1H), 3.01 (d, $J = 13.8$ Hz, 1H) ppm. $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ : 200.07, 149.53, 136.16, 133.82, 133.42, 130.51, 128.31, 128.25, 127.38, 126.27, 124.97, 121.14 (q, $J = 258.8$ Hz), 87.04, 42.22, 35.52 ppm. $^{19}\text{F NMR}$

(282 MHz, CDCl₃) δ : -51.67 (s, 3F) ppm. **IR** (NaCl): ν = 3033, 2929, 1730, 1608, 1496, 1456, 1265, 1043, 757, 701 cm⁻¹. **HRMS** (ESI) *m/z*: [M+Na]⁺ Calcd. for C₁₇H₁₃F₃NaO₂⁺ 329.0760; Found 329.0765.

(+)-2-(4-Fluorobenzyl)-2-(trifluoromethoxy)-2,3-dihydro-1H-inden-1-one ((+)-**3ab**). The reaction was run according to the general procedure. Eluent (*n*-hexane/ethyl acetate = 15/1). Slightly yellow oil; 26.9 mg; 83% yield. The enantiomeric excess (53% ee) was determined by chiral HPLC using CHIRALCEL® OJ-H (*n*-hexane/isopropanol = 99.0/1.0, flow rate 1.0 mL/min, λ = 254 nm) *t* (major) = 19.383 min, *t* (minor) = 11.833 min). [α]_D²⁵ = +29.6 (CH₂Cl₂, *c* = 0.76). **¹H NMR** (300 MHz, CDCl₃) δ : 7.77 (d, *J* = 7.7 Hz, 1H), 7.61 (t, *J* = 7.5 Hz, 1H), 7.41 – 7.33 (m, 2H), 7.17 – 7.12 (m, 2H), 6.91 (t, *J* = 8.4 Hz, 2H), 3.42 (d, *J* = 4.3 Hz, 2H), 3.27 (d, *J* = 14.0 Hz, 1H), 3.00 (d, *J* = 14.0 Hz, 1H) ppm. **¹³C NMR** (126 MHz, CDCl₃) δ : 199.84, 162.16 (d, *J* = 246.2 Hz), 149.37, 136.30, 133.36, 132.02 (d, *J* = 8.0 Hz), 129.50 (d, *J* = 3.2 Hz), 128.38, 126.29, 124.98, 121.12 (q, *J* = 258.8 Hz), 115.24 (d, *J* = 21.4 Hz), 86.87, 41.50, 35.56 ppm. **¹⁹F NMR** (282 MHz, CDCl₃) δ : -51.72 (s, 3F), -115.49 – -115.59 (m, 1F) ppm. **IR** (NaCl): ν = 3045, 2931, 1730, 1606, 1512, 1469, 1265, 1159, 838, 744 cm⁻¹. **HRMS** (ESI) *m/z*: [M+Na]⁺ Calcd. for C₁₇H₁₂F₄NaO₂⁺ 347.0666 Found 347.0669.

(+)-2-(4-Bromobenzyl)-2-(trifluoromethoxy)-2,3-dihydro-1H-inden-1-one ((+)-**3ac**). The reaction was run according to the general procedure. Eluent (*n*-hexane/ethyl acetate = 15/1). Slightly yellow semi-solid; 28.9 mg; 75% yield. The enantiomeric excess (41% ee) was determined by chiral HPLC using CHIRALCEL® OJ-H (*n*-hexane/isopropanol = 99.0/1.0, flow rate 1.0 mL/min, λ = 254 nm) *t* (major) = 33.433 min, *t* (minor) = 13.825 min). [α]_D²⁵ = +22.8 (CH₂Cl₂, *c* = 0.84). **¹H NMR** (300 MHz, CDCl₃) δ : 7.79 (d, *J* = 7.7 Hz, 1H), 7.62 (t, *J* = 7.5 Hz, 1H), 7.43 – 7.34 (m, 4H), 7.07 (d, *J* = 8.2, 2H), 3.47 – 3.33 (m, 2H), 3.25 (d, *J* = 14.0 Hz, 1H), 2.95 (d, *J* = 14.0 Hz, 1H) ppm. **¹³C NMR** (126 MHz, CDCl₃) δ : 199.66, 149.29, 136.37, 133.22, 132.86, 132.16, 131.47, 128.45, 126.35, 125.07, 121.61, 121.08 (q, *J* = 259.0 Hz), 86.63, 41.65, 35.54 ppm. **¹⁹F NMR** (282 MHz, CDCl₃) δ : -51.75 (s, 3F) ppm. **IR** (NaCl): ν = 3074, 2929, 1730, 1608, 1489, 1265, 1201, 1153, 1012, 519 cm⁻¹. **HRMS** (ESI) *m/z*: [M+Na]⁺ Calcd. for C₁₇H₁₂BrF₃NaO₂⁺ 406.9865 Found 406.9865.

(+)-2-(Trifluoromethoxy)-2-(4-(trifluoromethyl)benzyl)-2,3-dihydro-1H-inden-1-one ((+)-**3ad**). The reaction was run according to the general procedure. Eluent (*n*-hexane/ethyl acetate = 15/1). Slightly yellow oil; 23.6 mg; 63% yield. The enantiomeric excess (40% ee) was determined by chiral HPLC using CHIRALCEL® OJ-H (*n*-hexane/isopropanol = 99.0/1.0, flow rate 1.0 mL/min, λ = 254 nm) *t* (major) = 48.208 min, *t* (minor) = 33.525 min). [α]_D²⁵ = +18.8 (CH₂Cl₂, *c* = 0.50). **¹H NMR** (300 MHz, CDCl₃) δ : 7.80 (d, *J* = 7.7 Hz, 1H), 7.63 (t, *J* = 7.5, 1H), 7.51 (d, *J* = 8.0 Hz, 2H), 7.42 (t, *J* = 7.4 Hz, 1H), 7.39 – 7.32 (m, 3H), 3.49 – 3.34 (m, 3H), 3.04 (d, *J* = 13.9 Hz, 1H) ppm. **¹³C NMR** (126 MHz, CDCl₃) δ : 199.42, 149.15, 138.06, 136.45, 133.13, 130.87, 129.72 (q, *J* = 32.5 Hz), 128.54, 126.39, 125.25 (q, *J* = 3.7 Hz), 125.15, 124.00 (q, *J* = 272.1 Hz), 121.07 (q, *J* = 259.2 Hz), 86.57, 42.03, 35.65 ppm. **¹⁹F NMR** (282 MHz, CDCl₃) δ : -51.82 (s, 3F), -63.14 (s, 3F) ppm. **IR** (NaCl): ν = 3076, 2937, 1732, 1610, 1419, 1327, 1267, 1162, 1068, 748 cm⁻¹. **HRMS** (ESI) *m/z*: [M+Na]⁺ Calcd. for C₁₈H₁₂F₆NaO₂⁺ 397.0634 Found 397.0638.

(+)-2-(3-Fluorobenzyl)-2-(trifluoromethoxy)-2,3-dihydro-1H-inden-1-one ((+)-**3ae**). The reaction was run according to the general procedure. Eluent (*n*-hexane/ethyl acetate = 15/1). Slightly yellow oil; 24.3 mg; 75% yield. The enantiomeric excess (47% ee) was determined by chiral HPLC using CHIRALCEL® OJ-H (*n*-hexane/isopropanol = 99.0/1.0, flow rate 1.0 mL/min, λ = 254 nm) *t* (major) = 14.050 min, *t* (minor) = 8.758 min). [α]_D²⁵ = +26.8 (CH₂Cl₂, *c* = 0.19). **¹H NMR** (300 MHz, CDCl₃) δ : 7.80 (d, *J* = 7.9 Hz, 1H), 7.65 – 7.59 (m, 1H), 7.43 – 7.35 (m, 2H), 7.25 – 7.17 (m, 1H), 6.98 – 6.89 (m, 3H), 3.43 (d, *J* = 3.3 Hz, 2H), 3.31 (d, *J* = 13.9 Hz, 1H), 2.99 (d, *J* = 13.9 Hz, 1H) ppm. **¹³C NMR** (126 MHz, CDCl₃) δ : 199.66, 162.49 (d, *J* = 246.1 Hz), 149.33, 136.33, 136.27 (d, *J* = 7.4 Hz), 133.26, 129.79 (d, *J* = 8.4 Hz), 128.42, 126.34, 126.25 (d, *J* = 2.9 Hz), 125.07, 121.09 (q, *J* = 258.9 Hz), 117.40 (d, *J* = 21.6 Hz), 114.43 (d, *J* = 20.9 Hz), 86.72, 41.90, 35.58 ppm. **¹⁹F NMR** (282 MHz, CDCl₃) δ : -51.75 (s, 3F), -113.50 – -113.58 (m, 1F) ppm. **IR** (NaCl): ν = 3070, 2931, 1732, 1610, 1489, 1448, 1265, 1149, 785 cm⁻¹. **HRMS** (ESI) *m/z*: [M+Na]⁺ Calcd. for C₁₇H₁₂F₄NaO₂⁺ 347.0666 Found 347.0672.

(+)-2-([1,1'-Biphenyl]-4-ylmethyl)-2-(trifluoromethoxy)-2,3-dihydro-1H-inden-1-one ((+)-**3af**). The reaction was run according to the general procedure. Eluent (*n*-hexane/ethyl acetate = 15/1). Slightly yellow oil; 31.0 mg; 81% yield. The enantiomeric excess (41% ee) was determined by chiral HPLC using CHIRALPAK® ID (*n*-hexane/isopropanol = 99.0/1.0, flow rate 1.0 mL/min, λ = 254 nm) *t* (major) = 10.408 min, *t* (minor) = 8.192 min). $[\alpha]_D^{25} = +27.3$ (CH₂Cl₂, *c* = 0.84). ¹H NMR (300 MHz, CDCl₃) δ : 7.80 (d, *J* = 7.7 Hz, 1H), 7.62 – 7.31 (m, 10H), 7.27 – 7.25 (m, 2H), 3.47 (s, 2H), 3.36 (d, *J* = 13.9 Hz, 1H), 3.05 (d, *J* = 13.9 Hz, 1H) ppm. ¹³C NMR (126 MHz, CDCl₃) δ : 200.04, 149.54, 140.49, 140.19, 136.21, 133.38, 132.89, 130.93, 128.75, 128.30, 127.34, 126.99, 126.96, 126.33, 125.01, 121.16 (q, *J* = 258.8 Hz), 87.06, 41.88, 35.61 ppm. ¹⁹F NMR (282 MHz, CDCl₃) δ : -51.64 (s, 3F) ppm. IR (NaCl): ν = 3032, 2937, 1730, 1608, 1487, 1265, 1201, 1151, 748 cm⁻¹. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd. for C₂₃H₁₇F₃NaO₂⁺ 405.1073 Found 405.1077.

(+)-2-(Naphthalen-2-ylmethyl)-2-(trifluoromethoxy)-2,3-dihydro-1H-inden-1-one ((+)-**3ag**). The reaction was run according to the general procedure. Eluent (*n*-hexane/ethyl acetate = 15/1). Slightly yellow oil; 30.3 mg; 85% yield. The enantiomeric excess (24% ee) was determined by chiral HPLC using CHIRALPAK® ID (*n*-hexane/isopropanol = 99.5/0.5, flow rate 1.0 mL/min, λ = 254 nm) *t* (major) = 9.708 min, *t* (minor) = 8.233 min). $[\alpha]_D^{25} = +18.1$ (CH₂Cl₂, *c* = 0.77). ¹H NMR (300 MHz, CDCl₃) δ : 7.82 – 7.26 (m, 11H), 3.54 – 3.39 (m, 3H), 3.16 (d, *J* = 13.9 Hz, 1H) ppm. ¹³C NMR (126 MHz, CDCl₃) δ : 200.07, 136.21, 133.33, 133.10, 132.47, 131.57, 129.53, 128.39, 128.29, 127.98, 127.65, 127.56, 126.33, 126.14, 125.95, 125.02, 121.16 (q, *J* = 258.9 Hz), 87.15, 42.26, 35.50 ppm. ¹⁹F NMR (282 MHz, CDCl₃) δ : -51.64 (s, 3F) ppm. IR (NaCl): ν = 3057, 2927, 1730, 1608, 1509, 1468, 1263, 1153, 1162, 1045, 742 cm⁻¹. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd. for C₂₁H₁₅F₃NaO₂⁺ 379.0916 Found 379.0917.

(+)-2-Benzyl-5-bromo-2-(trifluoromethoxy)-2,3-dihydro-1H-inden-1-one ((+)-**3ba**). The reaction was run according to the general procedure. Eluent (*n*-hexane/ethyl acetate = 15/1). Slightly yellow solid; 35.8 mg; 93% yield. The enantiomeric excess (57% ee) was determined by chiral HPLC using CHIRALCEL® OJ-H (*n*-hexane/isopropanol = 99.0/1.0, flow rate 1.0 mL/min, λ = 254 nm) *t* (major) = 13.833 min, *t* (minor) = 18.725 min). $[\alpha]_D^{25} = +12.5$ (CH₂Cl₂, *c* = 0.31). ¹H NMR (300 MHz, CDCl₃) δ : 7.63 (d, *J* = 8.4 Hz, 1H), 7.53 – 7.51 (m, 2H), 7.32 – 7.06 (m, 5H), 3.41 (s, 2H), 3.30 (d, *J* = 13.8 Hz, 1H), 3.02 (d, *J* = 13.8 Hz, 1H) ppm. ¹³C NMR (126 MHz, CDCl₃) δ : 198.92, 151.00, 133.42, 132.26, 131.99, 131.66, 130.47, 129.58, 128.43, 127.55, 126.09, 121.09 (q, *J* = 259.1 Hz), 86.77, 42.15, 35.21 ppm. ¹⁹F NMR (282 MHz, CDCl₃) δ : -51.71 (s, 3F) ppm. IR (NaCl): ν = 3031, 2929, 1734, 1263, 1203, 1151, 1058, 704, 573 cm⁻¹. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd. for C₁₇H₁₂BrF₃NaO₂⁺ 406.9865; Found 406.9864. **m.p.**: 53.6 – 55.8 °C.

(+)-2-Benzyl-5-fluoro-2-(trifluoromethoxy)-2,3-dihydro-1H-inden-1-one ((+)-**3ca**). The reaction was run according to the general procedure. Eluent (*n*-hexane/ethyl acetate = 15/1). Slightly yellow oil; 23.0 mg; 71% yield. The enantiomeric excess (51% ee) was determined by chiral HPLC using CHIRALCEL® OJ-H (*n*-hexane/isopropanol = 99.0/1.0, flow rate 1.0 mL/min, λ = 254 nm) *t* (major) = 28.833 min, *t* (minor) = 27.167 min). $[\alpha]_D^{25} = +27.0$ (CH₂Cl₂, *c* = 0.77). ¹H NMR (300 MHz, CDCl₃) δ : 7.81 – 7.76 (m, 1H), 7.23 – 7.17 (m, 5H), 7.07 (t, *J* = 8.8 Hz, 1H), 6.99 (d, *J* = 8.2 Hz, 1H), 3.42 (s, 2H), 3.31 (d, *J* = 13.8 Hz, 1H), 3.05 (d, *J* = 13.8 Hz, 1H) ppm. ¹³C NMR (126 MHz, CDCl₃) δ : 198.16, 167.78 (d, *J* = 259.1 Hz), 152.48 (d, *J* = 10.5 Hz), 133.47, 130.46, 129.94 (d, *J* = 1.9 Hz), 128.39, 127.51, 127.48 (d, *J* = 10.5 Hz), 121.12 (q, *J* = 259.0 Hz), 116.73 (d, *J* = 23.7 Hz), 113.09 (d, *J* = 22.7 Hz), 86.97, 42.20, 35.58 ppm. ¹⁹F NMR (282 MHz, CDCl₃) δ : -51.72 (s, 3F), -99.80 (q, *J* = 7.1 Hz, 1F) ppm. IR (NaCl): ν = 3028, 2929, 1734, 1616, 1595, 1263, 1200, 1151, 702 cm⁻¹. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd. for C₁₇H₁₂F₄NaO₂⁺ 347.0666 Found 347.0672.

(+)-2-Benzyl-6-fluoro-2-(trifluoromethoxy)-2,3-dihydro-1H-inden-1-one ((+)-**3da**). The reaction was run according to the general procedure. Eluent (*n*-hexane/ethyl acetate = 15/1). Slightly yellow oil; 26.6 mg; 82% yield. The enantiomeric excess (56% ee) was determined by chiral HPLC using CHIRALCEL® OJ-H (*n*-hexane/isopropanol = 99.0/1.0, flow rate 1.0 mL/min, λ = 254 nm) *t* (major) = 13.792 min, *t* (minor) = 9.725 min). $[\alpha]_D^{25} = +22.2$ (CH₂Cl₂, *c* = 0.80). ¹H NMR (300 MHz, CDCl₃) δ : 7.40

(d, $J = 7.0$ Hz, 1H), 7.29 (d, $J = 5.1$ Hz, 2H), 7.23 – 7.14 (m, 5H), 3.40 (s, 2H), 3.30 (d, $J = 13.8$ Hz, 1H), 3.05 (d, $J = 13.7$ Hz, 1H) ppm. $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ : 199.35, 162.43 (d, $J = 249.8$ Hz), 145.02 (d, $J = 2.3$ Hz), 135.14 (d, $J = 7.5$ Hz), 133.45, 130.44, 128.38, 127.84 (d, $J = 7.8$ Hz), 127.51, 123.92 (d, $J = 23.7$ Hz), 121.12 (q, $J = 258.9$ Hz), 110.69 (d, $J = 22.2$ Hz), 87.49, 42.27, 35.10 ppm. $^{19}\text{F NMR}$ (282 MHz, CDCl_3) δ : -51.73 (s, 3F), -112.86 (q, $J = 6.9$ Hz, 1F) ppm. **IR** (NaCl): $\nu = 3033, 2947, 1736, 1614, 1489, 1265, 1200, 1155, 775, 702$ cm^{-1} . **HRMS** (ESI) m/z : $[\text{M}+\text{Na}]^+$ Calcd. for $\text{C}_{17}\text{H}_{12}\text{F}_4\text{NaO}_2^+$ 347.0666 Found 347.0671.

(+)-2-Benzyl-6-methyl-2-(trifluoromethoxy)-2,3-dihydro-1H-inden-1-one ((+)-**3ea**). The reaction was run according to the general procedure. Eluent (*n*-hexane/ethyl acetate = 15/1). Slightly yellow oil; 27.2 mg; 85% yield. The enantiomeric excess (29% ee) was determined by chiral HPLC using CHIRALCEL® OJ-H (*n*-hexane/isopropanol = 99.0/1.0, flow rate 1.0 mL/min, $\lambda = 254$ nm) t (major) = 17.217 min, t (minor) = 8.958 min). $[\alpha]_D^{25} = +20.0$ (CH_2Cl_2 , $c = 0.82$). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ : 7.58 (s, 1H), 7.41 (d, $J = 7.8$ Hz, 1H), 7.26 – 7.17 (m, 6H), 3.37 (s, 2H), 3.30 (d, $J = 13.8$ Hz, 1H), 2.98 (d, $J = 13.9$ Hz, 1H), 2.38 (s, 3H) ppm. $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ : 200.12, 146.90, 138.35, 137.45, 133.98, 133.47, 130.54, 128.29, 127.33, 125.98, 124.84, 121.14 (q, $J = 258.5$ Hz), 87.37, 42.22, 35.14, 21.11 ppm. $^{19}\text{F NMR}$ (282 MHz, CDCl_3) δ : -51.68 (s, 3F) ppm. **IR** (NaCl): $\nu = 3034, 2929, 1727, 1495, 1265, 1153, 702$ cm^{-1} . **HRMS** (ESI) m/z : $[\text{M}+\text{Na}]^+$ Calcd. for $\text{C}_{18}\text{H}_{15}\text{F}_3\text{NaO}_2^+$ 343.0916; Found 343.0913.

(+)-2-Benzyl-6-methoxy-2-(trifluoromethoxy)-2,3-dihydro-1H-inden-1-one ((+)-**3fa**). The reaction was run according to the general procedure. Eluent (*n*-hexane/ethyl acetate = 10/1). Yellow solid; 30.9 mg; 92% yield. The enantiomeric excess (33% ee) was determined by chiral HPLC using CHIRALCEL® OJ-H (*n*-hexane/isopropanol = 99.0/1.0, flow rate 1.0 mL/min, $\lambda = 254$ nm) t (major) = 26.942 min, t (minor) = 16.517 min). $[\alpha]_D^{25} = +29.2$ (CH_2Cl_2 , $c = 0.67$). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ : 7.26 – 7.17 (m, 8H), 3.83 (s, 3H), 3.35 (s, 2H), 3.30 (d, $J = 13.8$ Hz, 1H), 3.00 (d, $J = 13.8$ Hz, 1H) ppm. $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ : 200.13, 159.80, 142.42, 134.48, 133.91, 130.50, 128.29, 127.37, 127.09, 125.69, 121.14 (q, $J = 258.8$ Hz), 105.79, 87.65, 55.64, 42.33, 34.87 ppm. $^{19}\text{F NMR}$ (282 MHz, CDCl_3) δ : -51.73 (s, 3F) ppm. **IR** (NaCl): $\nu = 3032, 2945, 1728, 1618, 1493, 1435, 1271, 1028, 769, 702$ cm^{-1} . **HRMS** (ESI) m/z : $[\text{M}+\text{Na}]^+$ Calcd. for $\text{C}_{18}\text{H}_{15}\text{F}_3\text{NaO}_3^+$ 359.0866; Found 359.0869. **m.p.**: 93.5 – 95.7 °C.

(+)-2-Benzyl-5,6-dimethoxy-2-(trifluoromethoxy)-2,3-dihydro-1H-inden-1-one ((+)-**3ga**). The reaction was run according to the general procedure. Eluent (*n*-hexane/ethyl acetate = 5/1). Orange solid; 24.9 mg; 68% yield. The enantiomeric excess (13% ee) was determined by chiral HPLC using a series of CHIRALPAK® IF and CHIRALPAK® IA-3 (*n*-hexane/isopropanol = 90.0/10.0, flow rate 1.0 mL/min, $\lambda = 254$ nm) t (major) = 15.475 min, t (minor) = 23.808 min). $[\alpha]_D^{25} = -4.5$ (CH_2Cl_2 , $c = 0.83$). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ : 7.27 – 7.18 (m, 6H), 6.72 (s, 1H), 3.93 (s, 3H), 3.90 (s, 3H), 3.34 – 3.29 (m, 3H), 3.02 (d, $J = 13.8$ Hz, 1H) ppm. $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ : 198.42, 156.63, 149.97, 145.30, 134.08, 130.51, 128.27, 127.32, 126.22, 121.16 (q, $J = 258.5$ Hz), 107.02, 104.96, 87.37, 56.34, 56.14, 42.31, 35.24 ppm. $^{19}\text{F NMR}$ (282 MHz, CDCl_3) δ : -51.72 (s, 3F) ppm. **IR** (NaCl): $\nu = 3030, 2939, 1716, 1591, 1502, 1268, 1196, 1146, 782, 702$ cm^{-1} . **HRMS** (ESI) m/z : $[\text{M}+\text{Na}]^+$ Calcd. for $\text{C}_{19}\text{H}_{17}\text{F}_3\text{NaO}_4^+$ 389.0971 Found 389.0976. **m.p.**: 101.4 – 105.2 °C.

(+)-2-Benzyl-2-(trifluoromethoxy)-3,4-dihydronaphthalen-1(2H)-one ((+)-**3ha**). The reaction was run according to the general procedure. Eluent (*n*-hexane/ethyl acetate = 10/1). Slightly yellow oil; 16.3 mg; 51% yield. The enantiomeric excess (8% ee) was determined by chiral HPLC using CHIRALCEL® OJ-H (*n*-hexane/isopropanol = 99.0/1.0, flow rate 1.0 mL/min, $\lambda = 254$ nm) t (major) = 22.442 min, t (minor) = 8.583 min). $[\alpha]_D^{25} = -0.1$ (CH_2Cl_2 , $c = 0.30$). $^1\text{H NMR}$ (300 MHz, CDCl_3) δ : 8.13 (dd, $J = 7.8, 1.5$ Hz, 1H), 7.55 (td, $J = 7.5, 1.5$ Hz, 1H), 7.38 (t, $J = 7.5$ Hz, 1H), 7.35 – 7.26 (m, 5H), 3.29 – 3.16 (m, 2H), 3.11 (t, $J = 6.3$ Hz, 2H), 2.49 (dt, $J = 14.1, 7.1$ Hz, 1H), 2.14 (dt, $J = 13.7, 5.1$ Hz, 1H) ppm. $^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ : 192.65, 142.15, 134.27, 134.25, 130.68, 130.63, 128.71, 128.68, 128.38, 127.33, 127.25, 121.09 (q, $J = 258.4$ Hz), 85.72, 39.78, 30.41, 26.01 ppm. $^{19}\text{F NMR}$ (282 MHz, CDCl_3) δ : -50.57 (s, 3F) ppm. **IR** (NaCl): $\nu = 3032, 2949, 1699, 1603, 1454, 1273, 1201, 1146, 908, 706$ cm^{-1} . **HRMS** (ESI) m/z : $[\text{M}+\text{Na}]^+$ Calcd. for $\text{C}_{18}\text{H}_{15}\text{F}_3\text{NaO}_2^+$ 343.0916 Found 343.0922.

(*R*)-2-Allyl-2-(trifluoromethoxy)-2,3-dihydro-1*H*-inden-1-one (**3ah**). The reaction was run according to the general procedure, and the product is consistent with previously reported characterization data. [46] Eluent (*n*-hexane/ethyl acetate = 15/1). Colorless oil; 11.0 mg; 43% yield. The enantiomeric excess (68% ee) was determined by chiral HPLC using a CHIRALCEL® OJ-H column (*n*-hexane/isopropanol = 98.0/2.0, flow rate 0.5 mL/min, λ = 254 nm) *t* (major) = 11.167 min, *t* (minor) = 9.975 min). $[\alpha]_D^{25} = +16.5$ (CHCl₃, *c* = 0.37). ¹H NMR (300 MHz, CDCl₃) δ : 7.82 (d, *J* = 7.7 Hz, 1H), 7.68 (t, *J* = 7.5 Hz, 1H), 7.46 – 7.42 (m, 2H), 5.67 (ddt, *J* = 17.3, 10.4, 7.2 Hz, 1H), 5.19 – 5.11 (m, 2H), 3.54 (d, *J* = 17.8 Hz, 1H), 3.41 (d, *J* = 17.8 Hz, 1H), 2.75 (dd, *J* = 14.0, 6.7 Hz, 1H), 2.55 (dd, *J* = 14.0, 7.5 Hz, 1H) ppm. ¹⁹F NMR (282 MHz, CDCl₃) δ : -51.90 (s, 3F) ppm.

(*R*)-2-Allyl-5-fluoro-2-(trifluoromethoxy)-2,3-dihydro-1*H*-inden-1-one (**3ch**). The reaction was run according to the general procedure, and the product is consistent with previously reported characterization data. [46] Eluent (*n*-hexane/ethyl acetate = 20/1). Colorless oil; 9.6 mg; 35% yield. The enantiomeric excess (70% ee) was determined by chiral HPLC using CHIRALPAK® IF column (*n*-hexane/TBME = 90.0/10.0, flow rate 0.5 mL/min, λ = 254 nm) *t* (major) = 15.192 min, *t* (minor) = 13.042 min). $[\alpha]_D^{25} = +19.7$ (CH₂Cl₂, *c* = 0.31). ¹H NMR (300 MHz, CDCl₃) δ : 7.85 (d, *J* = 4.5 Hz, 1H), 7.18 – 7.12 (m, 2H), 5.67 – 5.60 (m, 1H), 5.21 – 5.12 (m, 2H), 3.53 (d, *J* = 18.0 Hz, 1H), 3.40 (d, *J* = 18.1 Hz, 1H), 2.79 – 2.72 (m, 1H), 2.60 – 2.52 (m, 1H) ppm. ¹⁹F NMR (282 MHz, CDCl₃) δ : -51.95 (s, 3F), -99.62 – -99.73 (m, 1F) ppm.

(*R*)-2-Allyl-6-methyl-2-(trifluoromethoxy)-2,3-dihydro-1*H*-inden-1-one (**3eh**). The reaction was run according to the general procedure, and the product is consistent with previously reported characterization data. [46] Eluent (*n*-hexane/ethyl acetate = 15/1). Colorless oil; 14.0 mg; 52% yield. The enantiomeric excess (45% ee) was determined by chiral HPLC using CHIRALPAK® IF column (*n*-hexane/TBME = 90.0/10.0, flow rate 0.5 mL/min, λ = 254 nm) *t* (major) = 15.992 min, *t* (minor) = 13.083 min). $[\alpha]_D^{25} = +16.2$ (CH₂Cl₂, *c* = 0.46). ¹H NMR (300 MHz, CDCl₃) δ : 7.61 (s, 1H), 7.49 (d, *J* = 7.9 Hz, 1H), 7.32 (d, *J* = 7.7 Hz, 1H), 5.70 – 5.59 (m, 1H), 5.18 – 5.10 (m, 2H), 3.48 (d, *J* = 17.7 Hz, 1H), 3.35 (d, *J* = 17.5 Hz, 1H), 2.76 – 2.69 (m, 1H), 2.57 – 2.50 (m, 1H), 2.41 (s, 3H) ppm. ¹⁹F NMR (282 MHz, CDCl₃) δ : -51.90 (s, 3F) ppm.

4. Conclusions

In conclusion, we disclose the organo-catalytic enantioselective benzylation reaction of α -OCF₃-indanones **1**. α -Benzyl- α -OCF₃-indanones **3** were synthesized in good to high yield with moderate enantioselectivity, up to 57% ee, and both enantiomers of **3** could be accessed by the selection of chiral PTC, **CN-4** or **CD-4**. The method was extended to the enantioselective allylation of **1**, and both enantiomers of α -allyl- α -OCF₃-indanones were also obtained in moderate yield with good ee, as much as 76% ee. To our knowledge, this is the first example of the asymmetric synthesis of trifluoromethoxylated compounds with a stereogenic OCF₃-carbon center, without the use of transition metals. Extension of this methodology to other OCF₃ ketones is underway, and will be reported in due course.

Supplementary Materials:

The following are available online at www.mdpi.com/xxx/s1, ¹H, ¹³C and ¹⁹F NMR spectra for desired compounds **3** and HPLC data for desired compounds **3**.

Author Contributions: N.S. conceived and designed the experiments and directed the project; M.M. Y.L. and Z.Z. performed the experiments; Y.L. analyzed the data; N.S. and Y.L. wrote the paper.

Funding: This work was supported by JSPS KAKENHI grants JP 18H02553 (KIBAN B) and JP 18H04401 (Middle Molecular Strategy).

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Gillis, E. P.; Eastman, K.J.; Hill, M.D.; Donnelly, D.J.; Meanwell, N.A. Applications of fluorine in medicinal chemistry. *J. Med. Chem.* **2015**, *58*, 8315-8359.
2. Berger, R.; Resnati, G.; Metrangolo, P.; Weber, E.; Hulliger, J. Organic fluorine compounds: a great opportunity for enhanced materials properties. *Chem. Soc. Rev.* **2011**, *40*, 3496-3508.
3. Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. Fluorine in medicinal chemistry. *Chem. Soc. Rev.* **2008**, *37*, 320-330.
4. Isanbor, C.; O'Hagan, D. Fluorine in medicinal chemistry: A review of anti-cancer agents. *J. Fluorine Chem.* **2006**, *127*, 303-319.
5. Müller, K.; Faeh, C.; Diederich, F. Fluorine in pharmaceuticals: looking beyond intuition. *Science* **2007**, *317*, 1881-1886.
6. Meanwell, N.A. Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design. *J. Med. Chem.* **2018**, *61*, 5822-5880.
7. Kawai, H.; Shibata, N. Asymmetric Synthesis of Agrochemically Attractive Trifluoromethylated Dihydroazoles and Related Compounds under Organocatalysis. *Chem. Rec.* **2014**, *14*, 1024-1040.
8. Shibata, N.; Mizuta, S.; Kawai, H. Recent advances in enantioselective trifluoromethylation reactions. *Tetrahedron: Asymmetry* **2008**, *19*, 2633-2644.
9. Zhu, Y.; Han, J.; Wang, J.; Shibata, N.; Sodeoka, M.; Soloshonok, V.A.; Coelho, J.A.; Toste, F.D. Modern approaches for asymmetric construction of carbon-fluorine quaternary stereogenic centers: synthetic challenges and pharmaceutical needs. *Chem. Rev.* **2018**, *118*, 3887-3964.
10. Mori, S.; Shibata, N. Synthesis and application of trifluoroethoxy-substituted phthalocyanines and subphthalocyanines. *Beilstein J. Org. Chem.* **2017**, *13*, 2273-2296.
11. Smart B E. Fluorine substituent effects (on bioactivity). *J. Fluorine Chem.* **2001**, *109*, 3-11.
12. Xu, X.H.; Matsuzaki, K.; Shibata, N. Synthetic methods for compounds having CF₃-S units on carbon by trifluoromethylation, trifluoromethylthiolation, triflylation, and related reactions. *Chem. Rev.* **2014**, *115*, 731-764.
13. Zhou, Y.; Wang, J.; Gu, Z.; Wang, S.; Zhu, W.; Aceña, J. L.; Soloshonok, V.A.; Izawa, K.; Liu, H. Next generation of fluorine-containing pharmaceuticals, compounds currently in phase II-III clinical trials of major pharmaceutical companies: new structural trends and therapeutic areas. *Chem. Rev.* **2016**, *116*, 422-518.
14. Shibata, N.; Ishimaru, T.; Nakamura, S.; Toru, T. New approaches to enantioselective fluorination: Cinchona alkaloids combinations and chiral ligands/metal complexes. *J. Fluorine Chem.* **2007**, *128*, 469-483.
15. Shimizu, M.; Hiyama, T. Modern synthetic methods for fluorine-substituted target molecules. *Angew. Chem. Int. Ed.* **2005**, *44*, 214-231.
16. Leroux, F.; Jeschke, P.; Schlosser, M. α -Fluorinated ethers, thioethers, and amines: anomerically biased species. *Chem. Rev.* **2005**, *105*, 827-856.
17. Landelle, G.; Panossian, A.; R Leroux, F. Trifluoromethyl ethers and-thioethers as tools for Medicinal chemistry and drug discovery. *Curr. Top. Med. Chem.* **2014**, *14*, 941-951.
18. Jeschke, P.; Baston, E.; Leroux, F. R. alpha-fluorinated ethers as "exotic" entity in medicinal chemistry. *Mini-Rev. Med. Chem.* **2007**, *7*, 1027-1034.
19. Kirsch, P.; Bremer, M. Nematic liquid crystals for active matrix displays: molecular design and synthesis. *Angew. Chem. Int. Ed.* **2000**, *39*, 4216-4235.
20. Mamada, M.; Shima, H.; Yoneda, Y.; Shimano, T.; Yamada, N.; Kakita, K.; Machita, T.; Tanaka, Y.; Aotsuka, S.; Kumaki, D.; Tokito, S. A unique solution-processable n-type semiconductor material design for high-performance organic field-effect transistors. *Chem. Mater.* **2014**, *27*, 141-147.
21. Coric, V.; Taskiran, S.; Pittenger, C.; Wasylinski, S.; Mathalon, D.H.; Valentine, G.; Saksa, J.; Gueorguieva, R.; Sanacora, G.; Malison, R.T.; Krystal, J.H. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. *Biol. Psychiatry* **2005**, *58*, 424-428.
22. Diacon, A.H.; Dawson, R.; von Groote-Bidlingmaier, F.; Symons, G.; Venter, A.; Donald, P.R.; van Niekerk, C.; Everitt, D.; Winter, H.; Becker, P.; Mendel, C.M. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. *Lancet* **2012**, *380*, 986-993.
23. Henne, K.R.; Tran, T.B.; VandenBrink, B.M.; Rock, D.A.; Aidasani, D.K.; Subramanian, R.; Mason, A.K.; Stresser, D.M.; Teffera, Y.; Wong, S.G.; Johnson, M.G. Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme. *Drug Metab. Dispos.* **2012**, *40*, 1429-1440.
24. Leo, A.; Hansch, C.; Elkins, D. Partition coefficients and their uses. *Chem. Rev.* **1971**, *71*, 525-616.

25. Hansch, C.; Leo, A.; Unger, S.H.; Kim, K.H.; Nikaitani, D.; Lien, E.J. Aromatic substituent constants for structure-activity correlations. *J. Med. Chem.* **1973**, *16*, 1207-1216.
26. Hansch, C.; Leo, A.; Taft, R.W. A survey of Hammett substituent constants and resonance and field parameters. *Chem. Rev.* **1991**, *91*, 165-195.
27. McClinton, M.A.; McClinton, D.A. Trifluoromethylations and related reactions in organic chemistry. *Tetrahedron* **1992**, *48*, 6555-6666.
28. Smart, B.E. Fluorine substituent effects (on bioactivity). *J. Fluorine Chem.* **2001**, *109*, 3-11.
29. Federsel, D.; Herrmann, A.; Christen, D.; Sander, S.; Willner, H.; Oberhammer, H. Structure and conformation of α, α, α -trifluoroanisole, $C_6H_5OCF_3$. *J. Mol. Struct.* **2001**, *567*, 127-136.
30. Böhm, H.J.; Banner, D.; Bendels, S.; Kansy, M.; Kuhn, B.; Müller, K.; Obst-Sander, U.; Stahl, M. Fluorine in medicinal chemistry. *ChemBioChem* **2004**, *5*, 637-643.
31. Farnham, W.B.; Smart, B.E.; Middleton, W.J.; Calabrese, J.C.; Dixon, D.A. Crystal and molecular structure of tris (dimethylamino) sulfonium trifluoromethoxide. Evidence for negative fluorine hyperconjugation. *J. Am. Chem. Soc.* **1985**, *107*, 4565-4567.
32. Taylor, S.L.; Martin, J.C. Trifluoromethyl triflate: synthesis and reactions. *J. Org. Chem.* **1987**, *52*, 4147-4156.
33. Marrec, O.; Billard, T.; Vors, J.P.; Pazenok, S.; Langlois, B.R. A deeper insight into direct trifluoromethoxylation with trifluoromethyl triflate. *J. Fluorine Chem.* **2010**, *131*, 200-207.
34. Sheppard, W.A. α -Fluorinated Ethers. I. Aryl Fluoroalkyl Ethers. *J. Org. Chem.* **1964**, *29*, 1-11.
35. Marrec, O.; Billard, T.; Vors, J.P.; Pazenok, S.; Langlois, B.R. A New and Direct Trifluoromethoxylation of Aliphatic Substrates with 2, 4-Dinitro (trifluoromethoxy) benzene. *Adv. Synth. Catal.* **2010**, *352*, 2831-2837.
36. Huang, C.; Liang, T.; Harada, S.; Lee, E.; Ritter, T. Silver-mediated trifluoromethoxylation of aryl stannanes and arylboronic acids. *J. Am. Chem. Soc.* **2011**, *133*, 13308-13310.
37. Chen, C.; Chen, P.; Liu, G. Palladium-catalyzed intramolecular aminotrifluoromethoxylation of alkenes. *J. Am. Chem. Soc.* **2015**, *137*, 15648-15651.
38. Chen, C.; Luo, Y.; Fu, L.; Chen, P.; Lan, Y.; Liu, G. Palladium-Catalyzed Intermolecular Ditrifluoromethoxylation of Unactivated Alkenes: CF_3O -Palladation Initiated by Pd (IV). *J. Am. Chem. Soc.* **2018**, *140*, 1207-1210.
39. Qi, X.; Chen, P.; Liu, G. Catalytic Oxidative Trifluoromethoxylation of Allylic C-H Bonds Using a Palladium Catalyst. *Angew. Chem. Int. Ed.* **2017**, *56*, 9517-9521.
40. Zhou, M.; Ni, C.; Zeng, Y.; Hu, J. Trifluoromethyl benzoate: a versatile trifluoromethoxylation reagent. *J. Am. Chem. Soc.* **2018**, *140*, 6801-6805.
41. Zheng, W.; Morales-Rivera, C.A.; Lee, J.W.; Liu, P.; Ngai, M.Y. Catalytic C-H Trifluoromethoxylation of Arenes and Heteroarenes. *Angew. Chem.* **2018**, *130*, 9793-9797.
42. Yang, H.; Wang, F.; Jiang, X.; Zhou, Y.; Xu, X.; Tang, P. Silver-Promoted Oxidative Benzylic C-H Trifluoromethoxylation. *Angew. Chem. Int. Ed.* **2018**, *57*, 13266-13270.
43. Jelier, B.J.; Triplet, P.F.; Pietrasiak, E.; Franzoni, I.; Jeschke, G.; Togni, A. Radical Trifluoromethoxylation of Arenes Triggered by a Visible-Light-Mediated N-O Bond Redox Fragmentation. *Angew. Chem. Int. Ed.* **2018**, *57*, 13784-13789.
44. Guo, S.; Cong, F.; Guo, R.; Wang, L.; Tang, P. Asymmetric silver-catalysed intermolecular bromotrifluoromethoxylation of alkenes with a new trifluoromethoxylation reagent. *Nat. Chem.* **2017**, *9*, 546.
45. Huang, W.; Wan, X.; Shen, Q. Enantioselective Construction of Trifluoromethoxylated Stereogenic Centers by a Nickel-Catalyzed Asymmetric Suzuki-Miyaura Coupling of Secondary Benzyl Bromides. *Angew. Chem. Int. Ed.* **2017**, *56*, 11986-11989.
46. Kondo, H.; Maeno, M.; Hirano, K.; Shibata, N. Asymmetric synthesis of α -trifluoromethoxy ketones with a tetrasubstituted α -stereogenic centre via the palladium-catalyzed decarboxylative allylic alkylation of allyl enol carbonates. *Chem. Commun.* **2018**, *54*, 5522-5525.
47. Kondo, H.; Maeno, M.; Sasaki, K.; Guo, M.; Hashimoto, M.; Shiro, M.; Shibata, N. Synthesis of chiral nonracemic α -difluoromethylthio compounds with tetrasubstituted stereogenic centers via a palladium-catalyzed decarboxylative asymmetric allylic alkylation. *Org. Lett.* **2018**, *20*, 7044-7048.
48. Chen, C.; Pflüger, P.M.; Chen, P.; Liu, G., Palladium (II)-Catalyzed Enantioselective Aminotrifluoromethoxylation of Unactivated Alkenes using $CsOCF_3$ as a Trifluoromethoxide Source. *Angew. Chem. Int. Ed.* **2019**, *58*, 2392-2396.

Sample Availability: Samples of the compounds **1a** and **3aa** are available from the authors.